The Effect of Edrecolomab (Mo17-1A) or Fluorouracil-Based Chemotherapy on Specific Immune Parameters in Patients with Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|67|5-6|403-410

ISSN： 0030-2414

Source： Oncology, Vol.67, Iss.5-6, 2005-02, pp. : 403-410

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thymidylate Synthase Expression in Normal Colonic Mucosa: A Predictive Marker of Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Adjuvant Chemotherapy

By  

Oncology, Vol. 67, Iss. 2, 2004-10 ,pp. : 135-142

Karger

Access to resources Recommend Favorite

Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 215-223

Karger

Access to resources Recommend Favorite

Oxaliplatin/5‐fluorouracil‐based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 334-342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-05 ,pp. : 407-415

Karger

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-, Fluorouracil-, and Leucovorin-Based Chemotherapy with Concomitant HAART in an HIV-Positive Patient with Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 31, Iss. 7, 2008-06 ,pp. : 394-397

Karger

Access to resources Recommend Favorite